LifeMD (LFMD) Set to Announce Earnings on Thursday

LifeMD (NASDAQ:LFMD) is set to announce its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. LifeMD has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.06). The business had revenue of $50.66 million during the quarter, compared to the consensus estimate of $48.47 million. During the same quarter in the previous year, the company posted ($0.23) earnings per share. On average, analysts expect LifeMD to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

LifeMD Price Performance

Shares of NASDAQ:LFMD opened at $4.15 on Thursday. The company has a market cap of $178.74 million, a P/E ratio of -5.93 and a beta of 1.18. The business has a fifty day simple moving average of $4.89 and a 200-day simple moving average of $6.81. LifeMD has a 52 week low of $3.99 and a 52 week high of $12.88. The company has a quick ratio of 0.83, a current ratio of 0.87 and a debt-to-equity ratio of 10.83.

Wall Street Analyst Weigh In

LFMD has been the subject of a number of research analyst reports. KeyCorp dropped their price objective on shares of LifeMD from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. B. Riley started coverage on shares of LifeMD in a research note on Friday, August 23rd. They set a “buy” rating and a $11.00 price target on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $15.00 price objective on shares of LifeMD in a research note on Friday, September 20th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $12.00.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.